Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PFSB to Draft GL for Registered Drug Sellers' Examination
September 25, 2006
- GENERIC NEWS IN BRIEF
September 25, 2006
- Zaditen Capsules Approved as Switch-OTC Drug
September 25, 2006
- TMRC Increasing Focus on Drug Discovery, Development: Dr Ekimoto
September 25, 2006
- Stomach Cancer Risk 10 Times Higher in H. pylori-Positive People
September 25, 2006
- SRI Int'l to Expand Business in Japan
September 25, 2006
- One in Five People Are Aware of Dysuria Symptoms: Pfizer Survey
September 25, 2006
- Bio Japan 2..6
September 25, 2006
- Shionogi, Nichia Celebrate 30th Anniversary of Nichia Pharmaceutical
September 25, 2006
- IHEP Symposium on Clinical Trials
September 25, 2006
- ELD to Focus on Improving Access to New Drugs
September 25, 2006
- Crestor's Safety Confirmed in Japanese Patients: AstraZeneca, Shionogi
September 25, 2006
- NIBIO Opens 2nd Invitation to FY2006 Basic Research Grants
September 25, 2006
- REGULATORY NEWS IN BRIEF
September 25, 2006
- Roche Actively Seeking R&D Partnerships in Japan: Dr Noguchi
September 25, 2006
- MEXT, METI, Korosho to Cooperate to Promote Translational Research
September 25, 2006
- Pneumococcal Vaccination in the Elderly Needs Government Support
September 25, 2006
- Kowa Pharmaceutical Aims for Sales of \74.8 Bil. in FY2007
September 25, 2006
- R&D NEWS IN BRIEF
September 25, 2006
- Once-weekly Osteoporosis Drug Both Effective and Convenient
September 25, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…